[
    [
        {
            "time": "2023-10-05",
            "original_text": "Pliant Therapeutics Up 33% on IPO Pricing",
            "features": {
                "keywords": [
                    "Pliant Therapeutics",
                    "IPO Pricing",
                    "Up 33%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 7,
                "Impact": 8,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 10,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "Novartis' sBLA for Ofatumumab Gets Extended Review From FDA",
            "features": {
                "keywords": [
                    "Novartis",
                    "Ofatumumab",
                    "Extended Review",
                    "FDA"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "The Daily Biotech Pulse: Regulatory Delay For Novartis Multiple Sclerosis Drug, FSD Gets Nod For COVID-19 Study",
            "features": {
                "keywords": [
                    "Regulatory Delay",
                    "Novartis",
                    "Multiple Sclerosis Drug",
                    "FSD",
                    "COVID-19 Study"
                ],
                "sentiment_score": -0.4,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotech",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "The Daily Biotech Pulse: Regulatory Delay For Novartis Multiple Sclerosis Drug, FSD Gets Nod For COVID-19 Study",
                "Correlation": 8,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]